To date, rs671 has not been studied as a potential predictor of ICI treatment, but it may have a complicated, bidirectional, and strong effect on ICI therapy for the following reasons: 1) Cancer cells of ALDH2*2 carriers may show more DNA damage induced by aldehyde exposure during smoking and drinking [15, 16], resulting in an increased presentation of antigens to immune cells, which is advantageous in ICI treatment. Here, ALDH2 is linked to cancer.